Which pharmacologic agent is preferred for women at very high risk of fracture?

Which pharmacologic agent is preferred for women at very high risk of fracture?

• A. Denosumab
• B. Anabolic agents (e.g., teriparatide, abaloparatide, romosozumab)
• C. Bisphosphonates
• D. Calcitonin

Answer: (B)

When fracture risk is very high, the goal is to rapidly build new bone and sharply reduce the chance of a fracture. Anabolic therapies directly stimulate bone formation, leading to quick and substantial gains in bone mineral density and strong reductions in fracture risk, especially for vertebral fractures. Teriparatide and abaloparatide are PTH pathway agents that activate osteoblasts to lay down new bone, producing meaningful bone quality improvements in a relatively short time. Romosozumab, with its dual action of increasing formation and decreasing resorption by inhibiting sclerostin, also delivers rapid, robust gains in bone mass and fracture protection, particularly in the first year. Because the benefits from anabolic therapy are time-limited, these agents are typically given for a defined period (for example, about a year) to quickly lower imminent fracture risk, and then a switch to an antiresorptive drug helps maintain the gains. Antiresorptives like bisphosphonates and denosumab reduce fracture risk as well, but their onset of protection is slower and the magnitude of early fracture risk reduction is generally smaller than what anabolic therapy achieves in the very high risk setting. Calcitonin has weaker effectiveness and is not favored for high-risk patients. So, for women at very high risk of fracture, an anabolic agent is the preferred choice because it offers the fastest and greatest impact on bone strength and fracture prevention, with a plan to transition to maintenance therapy afterward.

When fracture risk is very high, the goal is to rapidly build new bone and sharply reduce the chance of a fracture. Anabolic therapies directly stimulate bone formation, leading to quick and substantial gains in bone mineral density and strong reductions in fracture risk, especially for vertebral fractures. Teriparatide and abaloparatide are PTH pathway agents that activate osteoblasts to lay down new bone, producing meaningful bone quality improvements in a relatively short time. Romosozumab, with its dual action of increasing formation and decreasing resorption by inhibiting sclerostin, also delivers rapid, robust gains in bone mass and fracture protection, particularly in the first year. Because the benefits from anabolic therapy are time-limited, these agents are typically given for a defined period (for example, about a year) to quickly lower imminent fracture risk, and then a switch to an antiresorptive drug helps maintain the gains.

Antiresorptives like bisphosphonates and denosumab reduce fracture risk as well, but their onset of protection is slower and the magnitude of early fracture risk reduction is generally smaller than what anabolic therapy achieves in the very high risk setting. Calcitonin has weaker effectiveness and is not favored for high-risk patients.

So, for women at very high risk of fracture, an anabolic agent is the preferred choice because it offers the fastest and greatest impact on bone strength and fracture prevention, with a plan to transition to maintenance therapy afterward.